Evaluating drug prices, availability, affordability, and price components: Implications for access to drugs in Malaysia

PLoS Medicine

Volumn 4, Issue 3, 2007, Pages 466-475

  Babar, Zaheer Ud Din ^a   Ibrahim, Mohamed Izham Mohamed ^a   Singh, Harpal ^b   Bukahri, Nadeem Irfan ^c   Creese, Andrew ^d  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b UCSI UNIVERSITY   (Malaysia)

^c INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^d Les Ventes de Bourse ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMITRIPTYLINE; AMLODIPINE; AMOXICILLIN PLUS CLAVULANIC ACID; BECLOMETASONE; COTRIMOXAZOLE; DIAZEPAM; DOXYCYCLINE; ENALAPRIL; ERYTHROMYCIN; FANSIDAR; FLUOXETINE; FLUPHENAZINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDINAVIR; METFORMIN; MEVINOLIN; NEVIRAPINE; NIFEDIPINE; OMEPRAZOLE; PHENYTOIN; PRAZOSIN; PROPRANOLOL; RANITIDINE; SALBUTAMOL; SIMVASTATIN; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE; ESSENTIAL DRUG;

ARTICLE; DRUG COST; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; MALAYSIA; ORGANIZATION AND MANAGEMENT; WORLD HEALTH ORGANIZATION; ECONOMICS; HEALTH CARE QUALITY; HEALTH CARE SURVEY; HEALTH ECONOMICS; HUMAN; PHARMACY; PUBLIC HEALTH; TIME;

COMMUNITY PHARMACY SERVICES; DRUGS, ESSENTIAL; ECONOMICS, MEDICAL; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALAYSIA; NATIONAL HEALTH PROGRAMS; PHARMACIES; QUALITY INDICATORS, HEALTH CARE; TIME FACTORS;

EID: 33947656506     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040082     Document Type: Article

References (45)

1. World Health Organization, Health Action International (2003) Medicine prices - A new approach to measurement. Geneva: World Health Organization. Available at: http://whqlibdoc.who.int/hq/2003/WHO_EDM_PAR_2003.2.pdf. Accessed: 15 February 2007.
2. Quick JD, Rankin JR, Laing RO, O'Connor RW, Hogerzeil HV, et al. editors (1997) Managing drug supply. 2nd Ed. West Hartford (Connecticut): Kumarian Press. pp. 7-9.
3. Shepard SD, Savedoff W, Hong PK (2002) Healthcare reform initiatives in Malaysia. Report of a consultation with the planning and development division, Ministry of Health, Kuala Lumpur, Malaysia October 16. Available at: http://www.who.int/health_financing/countries/en/malaysia.pdf. Accessed: 20 February 2007.
4. Netto A (1999 June 19) Doctors buck privatisation of healthcare. Asia Times. Available at: http://www.atimes.com/se-asia/AF19Ae01.html. Accessed: 19 December 2006.
5. Cruez AF (2004 December 20) The income will decide the amount you pay. The Star (Malaysia). Available at: http://202.144.202.76/new_mps/cfm/ localnews_view.cfm?id=722. Accessed 15 February 2007.
6. World Health Organization (2005) World Health Statistics 2005. Available at: http://www.who.int/healthinfo/statistics/whostat2005en1.pdf. Accessed 17 December 2006.
7. Consumers Association of Penang(2004) High cost of medical care. Penang (Malaysia): Consumer Association of Penang. The Money Book. pp. 184-185.
8. Lek CS (2005 December 14) Health plan to be modelled after Sosco. The Star (Malaysia). Available at: http://202.144.202.76/new_mps/cfm/localnews_view. cfm?id=822. Accessed: 15 February 2007.
9. (2004 December 4) Hospital drugs to cost more. New Strait Times (Malaysia). Available at: http://202.144.202.76/new_mps/cfm/localnews_view.cfm? id=714. Accessed: 15 February 2007.
10. Consumers Association of Penang (1994) Memorandum on drug prices in Malaysia - The need for control. Penang (Malaysia): Consumer Association of Penang. pp. 1-15.
11. (2004 July 13) Prices of drugs way too high. The Star (Malaysia). Available at: http://202.144.202.76/new_mps/cfm/localnews_view.cfm?id1/4647. Accessed: 15 February 2007.
12. Azmi IM, Alavi R (2001) TRIPS, patents, technology transfer, foreign direct investment and the pharmaceutical industry in Malaysia. J World Intellect Prop 4: 947-974.
13. Babar ZU, Ibrahim M Izham M, Bukhari NI (2004) Effect of privatization of the drug distribution system on the prices of anti-infectives in Malaysia. J Pharm Finance Econ Policy 13: 3-26.
14. Babar ZU, Ibrahim M Izham M, Bukhari NI (2005) A pricing analysis of cardiovascular and blood products after privatization of dug distribution system in Malaysia. J Pharm Finance Econ Policy 14: 3-25.
15. Sangaralingam M, Raman M (2003) The high cost of private monopolies, 2003 original report, Malaysia. Available at: http://www.sowatch.org.uy/en/ informmesNacionales/351.html. Accessed 10 January 2005.
16. Baber ZU, Izham M Ibrahim M (2003) Affordability of medicines in Malaysia - Consumer perceptions. Essent Drugs Monit 33: 18-19.
17. Babar ZU, Izham M Ibrahim M, Bukhari NI (2005) Medicine utilization and pricing: The findings of a household survey in Malaysia. J Gener Med 3: 47-61.
18. McFadyen JE (2004) International drug price indicator guide 2003. Boston: Management Sciences for Health. pp. E3 to P2-18.
19. Gelders S, Ewen M, Noguchi N, Laing R (2006) Price, availability and affordability: An international comparison of chronic disease medicines. World Health Organization and Health Action International, Cairo, 2006. Available at: http://mednet3.who.int/medprices/CHRONIC.pdf. Accessed 20 December 2006.
20. World Health Organization, Health Action International (2004) Price component handbook. Geneva: WHO.
21. (2000) Malaysian national essential drug list. Kuala Lumpur (Malaysia): Ministry of Health. Available at: http://www.pharmacy.gov.my/html/nedl- hyperlinked.pdf. Accessed 15 February 2007.
22. (2006) Ministry of Health drug formulary. Kuala Lumpur (Malaysia): Ministry of Health, Pharmaceutical Services Division. Available at: http://www.pharmacy.gov.my/html/Formulari_List_Feb_2006.xls
23. Tripathi SK, Dey D, Hazra A (2005) Medicine prices and availability in the state of West Bengal, India. Available at: http://www.haiweb.org/ medicineprices/surveys/200412IW/survey_report.pdf. Accessed 18 December 2006.
24. Kotwani A (2004) Medicine prices in the state of Rajasthan, India. Available at: http://www.haiweb.org/medicineprices/surveys/200306IN/ survey_report.pdf. Accessed 22 June 2006.
25. Wickremasinghe R (2006) Evidence, policy and advocacy workshop on medicine prices. 2006 June 14-15;Kandy, Sri Lanka. Organized by World Health Organization and Health Action International.
26. Zulkefli AS (2006 July 1) Move to cap prices of essential medicines. New Strait Times. Available at: http://202.144.202.76/new_mps/cfm/localnews_view. cfm?id=873. Accessed 12 November 2006.
27. WHO Regional Office for the Western Pacific (2002) Revised, November. Manila: Western Pacific Region Health Data Bank.
28. Health Action International (2006) Medicine prices survey profile and reports. Available at: http://www.haiweb.org/medicineprices/survey_results.php. Accessed 12 September 2006.
29. Health Action International (2006) Survey results for India, Maharashtra (4 regions), Jan 2005. Available at: http://www.haiweb.org/medicineprices/ survey_results.php? sr=200501IG. Accessed 16 October 2006.
30. Trap B, Hansen EH, Hogerzeil HV (2002) Prescribing habits of dispensing and non-dispensing doctors in Zimbabwe. Health Policy and Plan 17: 288-295.
31. Kolassa EM (1997) Prices politic, and problems - A pricing philosophy. J Pharm Mark Pract 1: 21-27.
32. Mahmood M, Bukhari NI (2002) Pharmaceutical management and marketing. Faisalabad (Pakistan): Tariq Academy. pp. 115-144.
33. (2003) What price competitiveness in the drug industry? Lancet 362: 257.
34. Wertheimer AI, Grumer SK (1992) Overview of international pharmacy pricing. Pharmacoeconomics 2: 449-455.
35. Danzon PM (2000) Making sense of drug prices. Regulation 23: 56-63.
36. Australian Government Productivity Commission (2001) International pharmaceutical price differences, research report. Canberra. Available: http://www.pc.gov.au/study/pbsprices/finalreport/pbsprices.pdf. Accessed 17 December 2006
37. Bloor K, Maynard A, Freemantle N (1996) Lessons from international experience in controlling pharmaceutical expenditures III: Regulating industry. BMJ 313: 33-35. Available: http://www.bmj.com/cgi/content/full/313/7048/33. Accessed 19 December 2006.
38. Department of Health, Pricing and Supply Branch (2003) Pharmaceutical price regulation scheme. Discussion paper, September 2003. http://www.dh.gov.uk/ assetRoot/04/06/73/32/04067332.PDF. Accessed 19 December 2006.
39. Gier HD (2003) Financing pharmaceutical care in the Dutch health system. J Pharm Finance Econ Policy 12: 181-188.
40. Sirkia T, Rajaniemi S (2003) Country report, Finland pharmaceutical pricing and reimbursement policies. European Commission. Available at: http://ec.europa.eu/enterprise/phabiocom/docs/tse/finland.pdf. Accessed:
41. Sarmiento AZ (1995) Alternate drug pricing policies in the Americas. Geneva: World Health Organization. Health Economics and Drugs, DAP Series No.1.WHO/DAP/95.6.
42. Kumar S (2004) India to extend price controls on drugs. BMJ 329: 368.
43. Patented Medicines Prices Review Board (2004) Frequently asked questions. Available at: http://www.pmprb-cepmb.gc.ca/english/home.asp?x=1. Accessed 11 August 2006.
44. Lexchin J (2003) The siren calls of new drugs. Expert Rev. Pharmacoeconomics Outcomes 3: 513-515.
45. (2003) National Medicine Policy Draft 7. Ministry of Health (Malaysia): Pharmaceutical Services Division. pp. 1-24.